News
SNY
45.44
-1.45%
-0.67
QUEBEC'S INESSS RECOMMENDS BEYFORTUS FOR THE PREVENTION OF RSV FOR ALL INFANTS 8 MONTHS OF AGE AND YOUNGER
Reuters · 8h ago
SANOFI-AVENTIS CANADA INC.: SANOFI WORKING WITH QUEBEC PROVINCIAL AUTHORITIES TO MAKE BEYFORTUS AVAILABLE FOR 2024-25 RSV SEASON
Reuters · 8h ago
Maintaining Buy Rating on Sanofi: A Resilient Financial Outlook Despite Currency Headwinds
TipRanks · 15h ago
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Amgen provides update on results of the Phase 2a trial for Tezspire in chronic obstructive pulmonary disease. Tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17%. The reduction was not statistically significant.
Benzinga · 1d ago
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
Novartis AG released data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta treatment for up to six years in recently diagnosed relapsing multiple sclerosis. The study showed 44% fewer relapses and reductions in MRI lesions.
Benzinga · 1d ago
Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease Activity
Sanofi reports new data from a Phase 2 study in relapsing multiple sclerosis. The company's CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity. Preliminary clinical results are promising with a low annual relapse rate, company says.
Benzinga · 1d ago
IGM BIOSCIENCES: UNDER AGREEMENT, WILL BE ELIGIBLE TO RECEIVE UP TO $1,065 MLN IN AGGREGATE DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES/TARGET
Reuters · 1d ago
Sanofi's CD40L Antibody: New 48-Week Phase 2 Data Support Frexalimab's Potential For High Sustained Efficacy In Multiple Sclerosis
Frexalimab is a non-lymphocyte depleting treatment for relapsing multiple sclerosis. 96% of participants in a study had no new lesions and an annualized relapse rate of 0.04 after 48 weeks. Sanofi has initiated global phase 3 studies of the drug.
Benzinga · 1d ago
International Wide-Moat Stocks On Sale - The April 2024 Heat Map
As of April 16, there were 80 international wide-moat stocks meeting Morningstar's criteria. Only 17.7% of this group of stocks earned a 5-star valuation rating. The heat map of the most investable candidates is a good indicator of the best companies on sale. Morningstar lists 80 international Wide-Moat Stocks On Sale.
Seeking Alpha · 1d ago
BRIEF-Sanofi: New frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
Sanofi: New frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis. Sanofi says new study shows positive results in 48-weeks. Company says new drug has potential to be a first-in-class treatment for the disease.
Reuters · 1d ago
VGK Vs. QQQ: How Europe's 'GRANOLAS' Could Outperform The US 'Magnificent 7'
Europe's 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. The "Magnificent 7" stocks in the US lead returns and headlines in Europe. The Magnificent 7 is a proxy for the Invesco QQQ and Europe's FTSE Europe ETF "VGK" In the past year, the Mag 7 has outperformed Europe's GRanOLAS.
Seeking Alpha · 2d ago
Eli Lilly's nationwide insulin pricing settlement called off
Eli Lilly's insulin pricing settlement called off. The settlement would have capped prices and provided $13.5 million to purchasers of Lilly's insulin drugs. A judge in February refused to certify a class in the case. Lilly says the plaintiffs' claims lacked merit.
Reuters · 2d ago
Weekly Report: what happened at SNY last week (0408-0412)?
Weekly Report · 3d ago
GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma
Healthcare GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma. A mid-stage trial indicated that the diabetes drug lixisenatide benefited patients with Parkinson's disease. The diabetes drug belongs to a popular class of obesity drugs called GLp-1 agonists.
Seeking Alpha · 6d ago
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
The European Medicines Agency has determined that there is no substantial evidence supporting a link between GLP-1 receptor agonists and suicidal or self-injurious thoughts and behaviors. The assessment comes following reports of suicidal thoughts or actions. The FDA also conducted a review of GLp-1 RAs.
Benzinga · 6d ago
BUZZ-Nurix Therapeutics drops after upsized $175 mln stock offering
Nurix Therapeutics Inc's shares down 5.3% at $16.30 premarket after upsized $175 mln stock offering. Biopharma firm Nurix announced 11.7 mln shares to be sold at $15 each. Nurix shares closed up 27% last week.
Reuters · 6d ago
UPDATE 4-EU regulator rules out link between weight-loss drugs and suicidal thoughts
EU regulator rules out link between weight-loss drugs and suicidal thoughts. Shares of Danish drugmaker Novo Nordisk rose more than 2% after the findings. The EU drug regulator found evidence that a class of diabetes and weight- loss drugs are linked to suicide thoughts.
Reuters · 6d ago
BRIEF-EMA's PRAC Finds No Causal Association Between GLP-1 Drugs And Suicidal And Self-Injurious Thoughts And Actions
EMA's PRAC Finds No Causal Association Between GLP-1 Drugs And Suicidal And Self-Injurious Thoughts And Actions. EMA: No evidence not to support link between drugs and suicidal thoughts and actions. Study found no association between the use of the drug and suicide-related thoughts.
Reuters · 6d ago
EMA'S PRAC: NO CAUSAL ASSOCIATION BETWEEN GLP-1 RECEPTOR AGONISTS & RISK OF SUICIDE-RELATED EVENTS IN PEOPLE WITH TYPE 2 DIABETES MELLITUS
Reuters · 6d ago
EMA'S PRAC: AGREED CONTENT OF THE DHPC WILL BE FORWARDED TO THE CHMP FOR ADOPTION FOR NEW RYBELSUS TABLETS (ORAL SEMAGLUTIDE)
Reuters · 6d ago
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.